EWTX - NASDAQ
Edgewise Therapeutics, Inc.
$36.21
-1.7%Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
At a Glance
Live SnapshotEdgewise Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Edgewise Therapeutics, Inc. Balance Sheet
EWTX • NASDAQ
| Edgewise Therapeutics, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
ASSETS | |||||||
CURRENT ASSETS | |||||||
61.1M | 41.7M | 86.1M | 22M | 15.6M | 104.9M | 23.7M | |
469M | 428.5M | 232.3M | 330M | 265.2M | 24.2M | 0.0 | |
530.1M | 470.2M | 318.4M | 351.9M | 280.8M | 129.1M | 23.7M | |
0.0 | 0.0 | 0.0 | 5.1M | 3M | 551K | 390K | |
13.3M | 5.3M | 8.6M | 0.0 | 0.0 | 0.0 | 0.0 | |
543.4M | 475.5M | 327M | 357M | 283.8M | 129.6M | 24M | |
NON-CURRENT ASSETS | |||||||
9.2M | 11.1M | 12.7M | 9.9M | 912K | 516K | 498K | |
0.0 | 262K | 348K | 251K | 548K | 975K | 0.0 | |
9.2M | 11.3M | 13M | 10.1M | 1.5M | 1.5M | 498K | |
552.6M | 486.8M | 340M | 367.1M | 285.2M | 131.1M | 24.5M | |
LIABILITIES | |||||||
CURRENT LIABILITIES | |||||||
6M | 5.6M | 4M | 6.1M | 3.8M | 1.6M | 667K | |
6M | 5.6M | 4M | 6.1M | 3.8M | 1.6M | 667K | |
0.0 | 7.2M | 6.1M | 5.8M | 3.9M | 2.3M | 132K | |
1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 996K | 980K | 608K | 0.0 | 0.0 | 0.0 | |
20.4M | 10.1M | 5.7M | 4M | 2.8M | 452K | 333K | |
27.4M | 23.9M | 16.8M | 16.6M | 10.5M | 4.3M | 1.1M | |
NON-CURRENT LIABILITIES | |||||||
3M | 0.0 | 0.0 | 0.0 | 0.0 | 160.2M | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 329K | 0.0 | 40.3M | |
3M | 3.7M | 4.4M | 3.8M | 329K | 160.2M | 40.3M | |
0.0 | 4.7M | 5.4M | 4.4M | 0.0 | 0.0 | 0.0 | |
30.3M | 27.6M | 21.2M | 20.4M | 10.9M | 164.6M | 41.4M | |
SHAREHOLDERS' EQUITY | |||||||
10K | 9K | 7K | 6K | 5K | 0.0 | 0.0 | |
0.0 | 837.4M | 563.5M | 492.7M | 351.9M | 727K | 171K | |
-546.4M | -378.6M | -244.8M | -144.6M | -77M | -34.1M | -17M | |
677K | 420K | 99K | -1.4M | -514K | 0.0 | 0.0 | |
1.1B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
522.3M | 459.2M | 318.8M | 346.7M | 274.4M | -33.4M | -16.9M | |
522.3M | 459.2M | 318.8M | 346.7M | 274.4M | -33.4M | -16.9M | |
SUMMARY | |||||||
552.6M | 486.8M | 340M | 367.1M | 285.2M | 131.1M | 24.5M | |
469M | 428.5M | 232.3M | 330M | 265.2M | 24.2M | 0.0 | |
4M | 4.7M | 5.4M | 4.4M | 0.0 | 160.2M | 0.0 | |
-57.2M | -36.9M | -80.7M | -17.6M | -15.6M | 55.3M | -23.7M | |
105,868,000 | 105,868,000 | 105,868,000 | 105,868,000 | 105,868,000 | 105,868,000 | 105,868,000 |
SEC Filings
EWTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 01, 2026 | May 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 04, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 20, 2025 | November 19, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 10, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 |
Related Guides
Continue your EWTX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.